Fertility and Sterility

Journal

Publication Venue For

  • Evidence-based treatments for couples with unexplained infertility: a guideline.  113:305-322. 2020
  • Interpretation of clinical trial results: a committee opinion.  113:295-304. 2020
  • Reproductive endocrinologists are the gatekeepers for male infertility care in North America: results of a North American survey on the referral patterns and characteristics of men presenting to male infertility specialists for infertility investigations.  112:657-662. 2019
  • Postoperative adhesions in gynecologic surgery: a committee opinion.  112:458-463. 2019
  • Defining what is normal: the key to the diagnosis of polycystic ovary syndrome (and any other disorder for that matter…).  111:681-682. 2019
  • Fertility treatment when the prognosis is very poor or futile: an Ethics Committee opinion.  111:659-663. 2019
  • Is antimüllerian hormone an early marker or an in utero effector of incipient polycystic ovary syndrome?.  111:264-265. 2019
  • Minimal difference in phenotype between adolescents and young adults with polycystic ovary syndrome.  111:389-396. 2019
  • Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.  110:364-379. 2018
  • Does the risk of diabetes and heart disease in women with polycystic ovary syndrome lessen with age?.  108:959-960. 2017
  • Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis.  106:1510-1520.e2. 2016
  • Criteria, prevalence, and phenotypes of polycystic ovary syndrome.  106:6-15. 2016
  • Evolutionary determinants of polycystic ovary syndrome: part 2.  106:42-47. 2016
  • Introduction: Determinants of polycystic ovary syndrome.  106:4-5. 2016
  • Evidence-based approach to unexplained infertility: a systematic review.  105:1566-1574.e1. 2016
  • Association study of androgen signaling pathway genes in polycystic ovary syndrome.  105:467-473.e4. 2016
  • How do patient perceived determinants influence the decision-making process to accept or decline preimplantation genetic screening?.  105:188-193. 2016
  • Berberine inhibits the proliferation of human uterine leiomyoma cells.  103:1098-1106. 2015
  • Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes.  104:1522-1526. 2015
  • Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the National Institutes of Health 1990 criteria.  101. 2014
  • Effect of bilateral oophorectomy on adrenocortical function in women with polycystic ovary syndrome.  99:599-604. 2013
  • Cervical mucus monitoring prevalence and associated fecundability in women trying to conceive.  100. 2013
  • Progesterone-dependent regulation of endometrial cannabinoid receptor type 1 (CB1-R) expression is disrupted in women with endometriosis and in isolated stromal cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)..  98:948-56.e1. 2012
  • Comparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome.  96:1043-1047. 2011
  • Reply of the authors.  96. 2011
  • Defining hirsutism in Chinese women: A cross-sectional study.  96:792-796. 2011
  • Defining case-control studies.  95. 2011
  • Type 2 diabetes susceptibility single-nucleotide polymorphisms are not associated with polycystic ovary syndrome.  95. 2011
  • National semen analysis reference range reporting: Adherence to the 1999 World Health Organization guidelines 10 years later.  95:2320-2323. 2011
  • Polycystic ovary syndrome: An ancient disorder?.  95:1544-1548. 2011
  • Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: A systematic review and meta-analysis.  95. 2011
  • Reanalyzing the modified Ferriman-Gallwey score: Is there a simpler method for assessing the extent of hirsutism?.  96. 2011
  • Replication of association of a novel insulin receptor gene polymorphism with polycystic ovary syndrome.  95. 2011
  • Association of cystic fibrosis genetic modifiers with congenital bilateral absence of the vas deferens.  94:2122-2127. 2010
  • Self-assessed knowledge of treatment and fertility preservation in young women with breast cancer.  94:2396-2398. 2010
  • Ovarian and adipose tissue dysfunction in polycystic ovary syndrome: report of the 4th special scientific meeting of the Androgen Excess and PCOS Society.  94:690-693. 2010
  • The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia.  94:684-689. 2010
  • Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria.  93:1938-1941. 2010
  • An investigation of the visual disturbances experienced by patients on clomiphene citrate.  93:1169-1172. 2010
  • Epigenetics in polycystic ovary syndrome: a pilot study of global DNA methylation.  94. 2010
  • Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome.  94. 2010
  • Degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS.  92:643-647. 2009
  • Effect of insulin and testosterone on androgen production and transcription of SULT2A1 in the NCI-h295r adrenocortical cell line.  92:793-797. 2009
  • Fifteen-year trend in the use of reproductive surgery in women in the United States.  92:727-735. 2009
  • Reply of the Authors: Criteria for the polycystic ovary syndrome.  92. 2009
  • Effect of sex steroids and insulin on dehydroepiandrosterone sulfate production by hepatoma G2 cells.  91:2551-2556. 2009
  • Reply of the Authors: Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome.  91. 2009
  • Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome.  91:1848-1852. 2009
  • The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.  91:456-488. 2009
  • Adipocytes from women with polycystic ovary syndrome demonstrate altered phosphorylation and activity of glycogen synthase kinase 3.  90:2291-2297. 2008
  • Racial differences in self-reported infertility and risk factors for infertility in a cohort of black and white women: The CARDIA Women's Study.  90:1640-1648. 2008
  • Effect of oral estrogen on substrate utilization in postmenopausal women.  90:1275-1278. 2008
  • Effect of a daily supplement of soy protein on body composition and insulin secretion in postmenopausal women.  88:1609-1617. 2007
  • Repeat vasectomy reversal yields high success rates.  88:217-219. 2007
  • Reply of the Authors.  88:249-250. 2007
  • Effect of female partner age on pregnancy rates after vasectomy reversal.  87:1340-1344. 2007
  • Preliminary evidence of glycogen synthase kinase 3 beta as a genetic determinant of polycystic ovary syndrome.  87:1473-1476. 2007
  • Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome.  87:862-869. 2007
  • Heritability of dehydroepiandrosterone sulfate in women with polycystic ovary syndrome and their sisters.  86:1688-1693. 2006
  • Select patients with hypogonadotropic hypogonadism may respond to treatment with clomiphene citrate.  86:1664-1668. 2006
  • Report on the Third Annual Meeting of the Androgen Excess Society, San Diego, California, June 3, 2005.  86:1318-1320. 2006
  • Difference in dietary intake between women with polycystic ovary syndrome and healthy controls.  86:411-417. 2006
  • Reproducibility of the adrenal androgen response to adrenocorticotropic hormone stimulation.  86:484-486. 2006
  • Ovarian expression of markers associated with proliferation or apoptosis in women with diminished ovarian reserve.  86:176-185. 2006
  • Family size in women with polycystic ovary syndrome.  85:1837-1839. 2006
  • Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation.  85:1425-1431. 2006
  • Role of diet in the treatment of polycystic ovary syndrome.  85:679-688. 2006
  • Reply of the Author [2].  85:530. 2006
  • Diagnosis, phenotype, and prevalence of polycystic ovary syndrome.  86:S7. 2006
  • Polycystic ovary syndrome in Mexican-Americans: Prevalence and association with the severity of insulin resistance.  84:766-769. 2005
  • Phenotypic spectrum of polycystic ovary syndrome: Clinical and biochemical characterization of the three major clinical subgroups.  83:1717-1723. 2005
  • Diagnostic criteria for polycystic ovary syndrome: A reappraisal.  83:1343-1346. 2005
  • Prevalence of CYP21 mutations and IRS1 variant among women with polycystic ovary syndrome and adrenal androgen excess.  83:371-375. 2005
  • Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment.  83:1454-1460. 2005
  • Role of a CYP17 polymorphism in the regulation of circulating dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome.  82:973-975. 2004
  • Potential cofounders in the laparoscopic detection of endometriosis [12] (multiple letters).  81:1722-1723. 2004
  • Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess.  81:126-131. 2004
  • Glucose action and adrenocortical biosynthesis in women with polycystic ovary syndrome.  81:120-125. 2004
  • Androgen excess is the key element in polycystic ovary syndrome.  80:252-254. 2003
  • We should avoid the indiscriminate use of insulin sensitizers in women with polycystic ovary syndrome.  80:264-265. 2003
  • Visualization of the epigastric vessels and bladder before laparoscopic trocar placement.  80:209-212. 2003
  • Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome.  79:932-937. 2003
  • Laparoscopic evaluation following failure to achieve pregnancy after ovulation induction with clomiphene citrate.  80:1450-1453. 2003
  • Role of reproductive surgeons and the Society of Reproductive Surgeons.  78:916-917. 2002
  • Effect of oral micronized progesterone on androgen levels in women with polycystic ovary syndrome.  77:1125-1127. 2002
  • Adrenal progestogen and androgen production in 21-hydroxylase-deficient nonclassic adrenal hyperplasia is partially independent of adrenocorticotropic hormone stimulation.  77:750-753. 2002
  • Should employer-sponsored health insurance benefits be made public?.  77:216-217. 2002
  • Fertility outcomes after electroejaculation in men with spinal cord injury [3].  78:429-431. 2002
  • Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus.  77:1095-1105. 2002
  • Electroejaculation and assisted reproductive technologies in the treatment of anejaculatory infertility.  76:1249-1255. 2001
  • Influence of insulin and testosterone on adrenocortical steroidogenesis in vitro: Preliminary studies.  76:730-735. 2001
  • Repeated freezing and thawing does not generally alter assay results for several commonly studied reproductive hormones.  76:823-825. 2001
  • Hyperandrogenemia in patients presenting with acne.  75:889-892. 2001
  • A one-year experience with a capitated health care plan for infertility.  75:749-753. 2001
  • Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS.  75:53-58. 2001
  • Altered autophosphorylation of the insulin receptor in the ovary of a woman with polycystic ovary syndrome.  75:625-628. 2001
  • A variant of the glucocorticoid receptor gene is not associated with adrenal androgen excess in women with polycystic ovary syndrome.  74:1237-1240. 2000
  • Examination of the chin or lower abdomen only for the prediction of hirsutism.  74:980-983. 2000
  • The time has come to simplify the evaluation of the hirsute patient.  74:870-872. 2000
  • Adrenocortical hyperresponsivity to adrenocorticotropic hormone: A mechanism favoring the normal production of cortisol in 21-hydroxylase-deficient nonclassic adrenal hyperplasia.  74:329-334. 2000
  • Prevalence of 21-hydroxylase-deficient nonclassic adrenal hyperplasia and insulin resistance among hirsute women from Puerto Rico.  74:59-62. 2000
  • Reproductive medicine and research: Contract laboratories vs. the university-based researcher.  73:677-679. 2000
  • 11β-Hydroxyandrostenedione and δ5-androstenediol as markers of adrenal androgen production in patients with 21-hydroxylase-deficient nonclassic adrenal hyperplasia.  72:996-1000. 1999
  • Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: A prospective study.  72:915-925. 1999
  • Adrenal androgen excess in hyperandrogenism: Relation to age and body mass.  71:671-674. 1999
  • Effect of seminal oxidative stress on fertility after vasectomy reversal.  71:249-255. 1999
  • Dopamine D3 receptor polymorphism is not associated with the polycystic ovary syndrome.  71:436-438. 1999
  • Preimplantation genetic diagnosis of Marfan syndrome with the use of fluorescent polymerase chain reaction and the automated laser fluorescence DNA sequencer.  71:163-166. 1999
  • Sperm retrieval and intracytoplasmic sperm injection in patients with prune-belly syndrome [2].  72:948-949. 1999
  • Idiopathic hirsutism: An uncommon cause of hirsutism in Alabama.  70:274-278. 1998
  • Comparison of low-technology and high-technology monitoring of clomiphene citrate ovulation induction.  70:165-168. 1998
  • Measurement of total serum testosterone levels using commercially available kits: High degree of between-kit variability.  69:286-292. 1998
  • Effect of ovarian steroid production on adrenal steroidogenesis? [6] (multiple letters).  70:1187-1189. 1998
  • Role of the ovary in the adrenal androgen excess of hyperandrogenic women.  69:851-859. 1998
  • Peripheral progesterone (P) levels and endometrial response to various dosages of vaginally administered P in estrogen-primed women.  68:810-815. 1997
  • Expectant management versus elective curettage for the treatment of spontaneous abortion.  68:601-606. 1997
  • Detection of CAH heterozygotes [5] (multiple letters).  68:182-184. 1997
  • Detection of CAH heterozygotes..  68. 1997
  • Comparison of the ultrasonic scalpel to CO2 laser and electrosurgery in terms of tissue injury and adhesion formation in a rabbit model.  67:382-386. 1997
  • Identification of early pregnancy landmarks by transvaginal sonography: Analysis by logistic regression.  68:168-170. 1997
  • Instrument cleaning services: A patch or another hale in the bucket? [2] (multiple letters).  68:566-567. 1997
  • Prevalence of hyperandrogenemia among nonhirsute oligo-ovulatory women.  67:569-572. 1997
  • There's a hole in my bucket: The cost of disposable instruments.  67:13-15. 1997
  • Luteal support with both estradiol and progesterone after clomiphene citrate stimulation for in vitro fertilization.  66:587-592. 1996
  • The effect of routine breast examination on serum prolactin levels.  65:869-870. 1996
  • Antisperm antibodies in infertile women: Subclass distribution of immunoglobulin (Ig) A antibodies and removal of IgA sperm-bound antibodies with a specific IgA1 protease.  63:63-70. 1995
  • delta 5-Androstene-3 beta,17 beta-diol in healthy eumenorrheic women: relationship to body mass and hormonal profile..  62:321-326. 1994
  • Blunt trocar laparoscopy.  61:1177-1180. 1994
  • Inhibition of adhesion reformation in the rabbit model by meclofenamate: An inhibitor of both prostaglandin and leukotriene production.  62:1262-1265. 1994
  • The hyperandrogenic-insulin-resistant acanthosis nigricans syndrome: Therapeutic response.  61:570-572. 1994
  • Δ5-Androstene-3β,17β-diol in healthy eumenorrheic women: Relationship to body mass and hormonal profile.  62:321-326. 1994
  • Comparison of intracervical, intrauterine, and intratubal techniques for donor insemination.  59:339-342. 1993
  • Credentialing for endoscopic surgery [5].  60:381-382. 1993
  • For sperm - Is closer to the egg an advantage or liability? [1].  60:376-377. 1993
  • Kallmann's syndrome: Pregnancy achieved through gamete intrafallopian transfer.  60:737-739. 1993
  • Laparoscopic surgery for ectopic pregnancies: Technology assessment and public health implications.  59:487-498. 1993
  • Allergic reactions to penicillin during in vitro fertilization and intrauterine insemination.  58:847-849. 1992
  • Elevated interleukin-6 levels in peritoneal fluid of patients with pelvic pathology.  58:302-306. 1992
  • Motility longevity of sperm samples processed for intrauterine insemination.  58:436-438. 1992
  • Operative endoscopy: The pressing need for a structured training and credentialing process.  58:1100-1102. 1992
  • The effect of cocaine on sperm motility characteristics and bovine cervical mucus penetration.  57:178-182. 1992
  • 11 beta-hydroxylase deficiency in hyperandrogenism..  55:733-741. 1991
  • Effect of estrogen/progestin administration on the ovarian response to gonadotropins: A randomized, prospective study.  55:642-643. 1991
  • Effect of obesity on the response to acute adrenocorticotropin stimulation in eumenorrheic women.  56:427-433. 1991
  • Magnetic resonance imaging of the adrenal gland in women with late-onset adrenal hyperplasia.  56:142-144. 1991
  • No acute effect of physiological insulin increase on dehydroepiandrosterone sulfate in women with obesity and/or polycystic ovarian disease.  56:1179-1182. 1991
  • The effects of three serotypes of Ureaplasma urealyticum on spermatozoal motility and penetration in vitro.  55:170-176. 1991
  • Detection of antigalactosyltransferase antibodies in plasma from patients with antisperm antibodies.  54:133-137. 1990
  • Hormonal treatment of functional ovarian cysts: A randomized, prospective study.  54:775-777. 1990
  • Late onset adrenal hyperplasia: Mutation at codon 282 of the functional 21-hydroxylase gene is not ubiquitous.  54:819-823. 1990
  • Performance anxiety during infertility treatment: Effect on semen quality.  53:337-340. 1990
  • Secretory immune system of the female reproductive tract. II. Local immune system in normal and infected fallopian tube.  54:51-55. 1990
  • Comparison between 1-hour and 24-hour follow-up radiographs in hysterosalpingography using oil based contrast media.  52:753-755. 1989
  • Postoperative recuperation: Relation to the extent of endoscopic surgery.  51:1061-1064. 1989
  • Reproductive endocrinologic alterations in female asymptomatic obesity.  52:703-725. 1989
  • Are we exploiting the infertile couple?.  48:735-739. 1987
  • Congenital adrenal hyperplasia: Long-term results following vaginal reconstruction.  46:1011-1014. 1986
  • Determination of antisperm antibodies in infertile couples by millititer filtration.  45:299-301. 1986
  • Long-term medical therapy and follow-up of pediatric-adolescent patients with prolactin-secreting macroadenomas.  45:713-716. 1986
  • Regulation of human prolactin secretion by gonadotropin-releasing hormone in vitro.  46:26-31. 1986
  • Report of the National Symposium on the Clinical Management of Prolactin-Related Reproductive Disorders..  45:607-610. 1986
  • Diagnosis and management of prolactinomas.  43:5-16. 1985
  • In vitro and in vivo evaluation of latex condoms using a two-phase nonoxynol 9 system.  43:931-936. 1985
  • Detection of ovulation.  41:680-681. 1984
  • Long-term monolayer culture of human anterior pituitary cells: Functional validation of a method.  41:75-80. 1984
  • Comparison of dopamine agonists in the treatment of hyperprolactinemic syndromes: A multicenter study.  39:744-748. 1983
  • Evaluation of Delestrogen and Parlodel as a luteolytic agent in humans.  37:213-217. 1982
  • Patients with unexplained infertility..  38:261-262. 1982
  • An estrogen-bromocriptine regimen as a potential means of fertility regulation.  35:241. 1981
  • Inhibition of peritoneal adhesion re-formation after lysis with thirty-two per cent dextran 70..  35:592-593. 1981
  • Microsurgical reversal of female sterilization..  36:122-123. 1981
  • Assessment of pituitary function in patients with serum prolactin levels greater than 100 ng/ml.  32:177-182. 1979
  • International Standard Serial Number (issn)

  • 0015-0282
  • Electronic International Standard Serial Number (eissn)

  • 1556-5653